BioMarin reported Q1 2026 results on May 4, with total revenues of $766 million (up YoY and beating some estimates, aided by VOXZOGO patient growth and enzyme therapies). While non-GAAP EPS of $0.76 missed expectations amid higher costs (including a $31 million manufacturing charge and acquisition-related expenses), the company sharply raised full-year 2026 total revenue guidance to $3.825–$3.925 billion (from $3.325–$3.425 billion). This reflects an accelerated ~20% YoY growth rate at the midpoint, primarily from the April 27 closing of the Amicus Therapeutics acquisition, which adds marketed products GALAFOLD and POMBILITI + OPFOLDA to the rare-disease portfolio. The outlook improvement and acquisition synergies have been highlighted positively by analysts (with several Buy/Outperform reaffirmations and select price target increases, such as Evercore ISI to $120), outweighing the near-term EPS shortfall and margin pressures. After an initial post-earnings dip on May 5, the stock rose ~2.55% on May 6; the additional ~4.4% premarket gain on May 7 appears to reflect continued digestion of this bullish longer-term outlook rather than a single new announcement.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.